{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 1, Open-Label Study that will test BMS-986393 in combination with 3 dual agent combinations of BMS-986393 (a chimeric antigen receptor CAR T-cell) with investigational treatments {Alnuctamab, Mezigdomide or Iberdomide} for safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics.","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-1-open-label-study-that-will-test-bms-986393-in-combination-with-3-dual-agent-combinations-of-bms-986393-a-chimeric-antigen-receptor-car-t-cell-with-investigational-treatments-alnuctamab\/#breadcrumbitem"}]}